Open AccessPatient selection and timing of allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma
Author(s) -
Fillon Mike
Publication year - 2018
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21426
Subject(s) - chemoimmunotherapy , follicular lymphoma , hematopoietic stem cell transplantation , medicine , transplantation , oncology , lymphoma , stem cell , disease , hematopoietic cell , haematopoiesis , rituximab , immunology , biology , genetics
Key Points Approximately 20% of patients with FL relapse within 2 years of diagnosis with decreasing sensitivity to treatment. Allo‐HCT is more effective in patients who are in earlier phases of the disease. Autologous hematopoietic cell transplantation should be considered as an option for high‐risk patients who experience failure of chemoimmunotherapy after initial lines of therapy.